GTCR related stories
All articles and analysis
PEC adds 18 members, changes nameThe Washington, DC trade group has more than doubled its membership to include mid-market firms, and has created a committee to consider issues relating to the small and mid-market.
- Maine considers early backing for GTCR X
Chicago-based GTCR plans to raise $3bn for its 10th fund.
- California firms agree placement ban
In relation to the pay-to-play scandal, Ares and Freeman Spogli have signed on to New York Attorney General Andrew Cuomo’s code of conduct that prohibits the use of placement agents.
- Turkish funds prepare for 'high growth'
Actera co-founder Murat Çavusoglu told a standing room only crowd at the PEI Turkey Forum that much has changed since local entrepreneurs used to cling to the Turkish saying, 'May God never force you to sell your company'.
- Bankruptcy battles
In several high-profile cases, investment performance will be determined by how well the GPs perform in bankruptcy situations, writes Christopher Witkowsky.
- TowerBrook tangles with GTCR in bankruptcy battle
TowerBrook has its sights on forcing the bankruptcy of a floundering portfolio company, Wilton Holdings, in which GTCR and co-investor Martha Stewart have some $200m in equity.
- GTCR invests $200m in specialty insurance company
The Chicago-based firm has been busy in the market downturn, spending nearly $500m in the past few months to set up platforms for medical devices and pharmaceuticals.
- GTCR acquires classic cartoon characters
The Chicago-based private equity firm’s $200m acquisition of Entertainment Rights’ subsidiaries gives it control over popular children’s characters like Frosty the Snowman, He-Man and Casper the Friendly Ghost.
- GTCR to invest $200m in pharma platform
Fresh from its $900m exit of Ovation Pharmaceuticals, US buyout veteran GTCR has established a buy-and-build platform for specialty pharmaceutical companies and products.
- GTCR lands $900m pharmaceutical exit
The Chicago-based private equity firm originally invested $150m in Ovation Pharmaceuticals seven years ago.